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Abstract
Background: Facial pain syndromes can be very heterogeneous and need individual diagnosis and
treatment. This report describes an interesting case of facial pain associated with eczema and an
isolated dyskinesia of the lower facial muscles following dental surgery. Different aspects of the
pain, spasms and the eczema will be discussed.
Case presentation: In this patient, persistent intense pain arose in the lower part of her face
following a dental operation. The patient also exhibited dyskinesia of her caudal mimic musculature
that was triggered by specific movements. Several attempts at therapy had been unsuccessful. We
performed local injections of botulinum toxin type A (BTX-A) into the affected region of the
patient's face. Pain relief was immediate following each set of botulinum toxin injections. The follow
up time amounts 62 weeks.
Conclusion: Botulinum toxin type A (BTX-A) can be a safe and effective therapy for certain forms
of facial pain syndromes.
Background
The underlying mechanism of a chronic pain syndrome
caused by alterations in the area of the trigeminal nerve
seems to be an increased activity in trigeminal nerve fibers
and an altered inhibition in the trigeminal nucleus. The
increased neuronal activity (idiopathic or symptomatic)
involves nociceptive neurons resulting in the perception
of pain [1-3].
Various possible etiologies of chronic facial pain syn-
dromes are known, including 1) disorders of the cranium,
neck, eyes, ears, nose, sinuses, teeth, mouth and other
facial structures and 2) cranial neuralgias, nerve trunk
pain and deafferentiation pain [3]. Facial pain is often
caused by cervical and other forms of dystonia, blepharos-
pasm, hemifacial spasm, Meige-syndrome, masticatory
hyperactivity, temporomandibular disorders (TMD),
bruxism, trigeminal and other cranial neuralgias, tension-
type headache or migraine.
Chronic facial pain can be difficult to manage [1]. One
cause of the pain syndromes may be an affliction of the
oral region in the form of lesions of peripheral trigeminal
nerve fibers. Atypical facial pain is known to be initiated
by surgical trauma in the oral region [4,5] and can also be
induced by altered muscle function with hypertonicity
[6].
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There are numerous descriptions in the literature of
patients with chronic facial pain or pain-associated dysto-
nias effectively treated by injecting botulinum toxin into
the involved areas [1,6-11], thus achieving total or partial
relief of symptoms without the necessity of systemic med-
ication with its often notable side effects. The long dura-
tion of the positive effects of botulinum toxin and the
highly limited systemic complications associated with its
use are important pharmacological features of this thera-
peutic option for the management of atypical facial pain
and chronic pain syndromes.
It is difficult to explain the mechanisms leading to the
analgesic effect of botulinum toxin used in the treatment
of chronic facial pain or painful muscle disorders. Here we
report an interesting case of facial pain with facial dyski-
nesia following dental surgery.
Case presentation
A 53-year-old female patient who had been suffering for
ten years from atypical facial pain combined with a partial
facial spasm was referred to our outpatient clinic.
She presented with continuous distorsions of the mimic
musculature in the region of the lower left lip, which had
appeared following severe osteomyelitis of the left side of
the mandible that had been treated surgically. For several
weeks following the operation the patient experienced
hypesthesia in the left mandibular region and skin. There-
after, constant, disturbing spasms of the mimic muscula-
ture occurred combined with dyskinesia and deep
spasmodic pain attacks located in her lower left lip region.
In addition, a distinct cutaneous erythema appeared in
the region of the dyskinesia (figure 1).
The patient reported that pain attacks occurred daily
immediately after awakening in the morning, continued
during the day without any improvement and subsided
only at bedtime.
There had been no satisfactory response to various neuro-
logical or dental therapy attempts nor to acupuncture.
Only therapy with carbamazepine had brought a slight
and transient relief of her symptoms.
The patient felt herself immensely restricted by her symp-
toms and was socially and professionally disabled. She
had had to retire because of the intolerable pain attacks,
and reported having suicidal thoughts from time to time.
During the following years she detected alleviation points
in her left hand and behind the left ear with which she was
able to stop the convulsions and the pain as long as pres-
sure was applied to the points (figure 2).
The patient had had no history of movement disorders
such as hemifacial spasms nor of allergy, smoking or alco-
holism. She had no history of medication except for car-
bamazepine.
On physical examination, no anatomic disorders, infec-
tions or tumors were found except for a discrete septum
deviation. We observed continuous spasms in the region
of her left lower lip, accompanied by an intense eczema in
this region. She was able to stop the spasms and the pain
by pressing the points on her hand or behind the ear.
The figure shows the point in the left hand that the patient  could press to stop the pain attacks and facial movements Figure 2
The figure shows the point in the left hand that the patient 
could press to stop the pain attacks and facial movements.
The eczema in the affected area disappeared after injection of  BTX-A Figure 1
The eczema in the affected area disappeared after injection of 
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After the patient had given informed consent, BTX-A-treat-
ment was begun. She was treated over a period of 67
weeks with seven different injections of BTX-A at different
time points.
The dose of BTX-A was increased from initially 5 units to
25 units at the seventh treatment. We also augmented the
number of injection points from 2 points to 10 points in
the affected area. Injections were made with 2.5 units per
site (Botox®, Allergan Inc, Irvine, California; 0.1 ml = 2.5
units BTX-A). The time between the treatment sessions
varied from 3 weeks to 24 weeks up to the last treatment.
For details see table 1.
BTX-A was injected into the inferior depressor labii mus-
cle in the left lower lip region. The seventh injection with
25 units injected into 10 points was the most effective
with an effect lasting 24 weeks (table 1).
The patient was immediately pain-free after the injections
and experienced other positive effects such as relief of
spasms and eczema. The symptoms improved already
after the first injection of botulinum toxin type A. At the
check-up, three weeks after the first injection, the patient
was free of symptoms and was very satisfied.
As agreed upon with the patient, she returned to our out-
patient clinic for further treatment whenever any symp-
toms reappeared.
The BTX-A injection was repeated after 5 weeks with a
total dose of 10 units at 4 injection points (4 injections à
2.5 units) because of mild spasms.
After the second injection, the patient again experienced a
reduction in pain, spasms and eczema for a period of 7
weeks, at which time we injected 15 units into 6 injection
points.
In the further course, the patient returned four more times
after 3, 11, 17 and 24 weeks for further injections with 20
to 25 units BTX-A into 8 to 10 injection sites. Fourteen
weeks after the last series, she reported in a telephone
interview that the excellent positive effects were long last-
ing and that she was not suffering from pain, spasms or
eczema.
The patient was able to reduce the dose of carbamazepine
considerably.
In the course of the treatment period, the duration of the
symptom-free period increased from a minimum of 3
weeks to 24 weeks. The longest positive effect was seen
after the injection of 25 units BTX-A into 10 injection
points in the lower left lip region.
The patient did not note any side effects except for a slight
leakage at the corner of her mouth lasting a few days,
which she did not find very irritating as the positive bene-
fits were much more important for her. A total follow-up
period of 62 weeks was observed in this patient.
In summary, the patient expressed great satisfaction and
stated: "A completely new period in my life began" after
the first injection.
Discussion
Botulinum toxin has been used for 20 years to treat vari-
ous neurological disorders associated with pathologically
increased muscle tone or impaired autonomic nerve regu-
lation [2,7,8,10-18]. In addition to the reduction in mus-
cle innervation, botulinum toxin tends to reduce pain in
focal dystonia, spasticity and other pain syndromes asso-
ciated with muscle spasm [7,19-24]. An additional analge-
sic mechanism in muscle disorders associated with pain is
conceivable, because pain relief does not necessarily cor-
relate with the amount and duration of the neuromuscu-
lar effects [9,12].
Göbel et al. [15] reported several non-neuromuscular
effects of the toxin as well as a normalization of increased
muscle spindle activity, decompression of afferent nocice-
ptive neurons of muscular and vascular tissue, retrograde
intake of botulinum toxin in the peripheral and central
nervous system with modulation of the central neuropep-
tide function, inhibition of sterile neurogenic inflamma-
tion and normalization of endplate dysfunction. It has
been supposed that the alteration of the motor reflex
activity may induce neuronal processes of central reorgan-
ization. BTX-A has also been shown to inhibit the release
of substance P, a neurotransmitter responsible for activa-
tion of neurogenic inflammatory processes, from trigemi-
nal nerve endings.
Table 1: Time course of treatment
Treatment Dose of 
BTX-A 
administered
Number of 
injections 
(à 2.5 units)
Time of injection
1 5 units 2 points Onset
2 10 units 4 points after 5 weeks
3 15 units 6 points after 2 weeks
4 20 units 8 points after 3 weeks
5 20 units 8 points after 11 weeks
6 25 units 10 points after 17 weeks
7 25 units 10 points after 24 weeks
Summary of treatment, dose, injection points and time points. BTX-A 
= botulinum toxin type A.Head & Face Medicine 2007, 3:32 http://www.head-face-med.com/content/3/1/32
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In our case, conclusive arguments pointing to the BTX A-
effect responsible for the clear improvement of the
patient's symptoms exist. One important point is the
reproducible improvement following BTX-A application
parallel to the reduced dyskinesia of the lower lip.
Another point is the recurrence of extensive pain symp-
toms when the full BTX-A effect decreased. This is moni-
tored and demonstrated by the simultaneous recurrence
of pathological movements of the lower lip. Another argu-
ment is the statement of the patient that the pain symp-
toms disappeared completely after the BTX-A injections.
However, it remains unclear whether the improvement is
directly caused by a BTX-A effect or is only a secondary
effect.
According to Göbel et al. [15], one can assume the exist-
ence of direct analgesic and neuromodulating mecha-
nisms of botulinum toxin in the central nervous system,
anti-inflammatory effects and effects on the myofascial
tender points.
At the beginning of the 20th century, Russel formulated
the hypothesis of a trigemino-facial reflex positing that
irritations of the trigeminal nerve lead to alterations in the
facial motor nucleus, and that spontaneous activity of the
facial nerve (muscle spasms) could occur. Dental, oph-
thalmic or otolaryngological diseases may act as trigger
mechanisms in this connection [25]. On the other hand,
the patient's complaints could be explained as a postsur-
gical pain syndrome due to chronic irritation of trigemi-
nal nerve fibers following osteomyelitis and dental
surgery. The simultaneous occurrence of pain and facial
spasms might suggest that the rhythmic contractions of
the facial muscles act as a facial trigger analogous to
trigeminal neuralgia which can be caused by ectopic firing
of injured nerve fibers [16].
According to Fromm et al. [2] and Göbel et al. [15],
chronic alterations in the dental and oral region might
induce degenerative changes in trigeminal axonal endings
and a reduced inhibition in the trigeminal nucleus, lead-
ing to pain [6]. Their hypothesis was that disease of the
trigeminal nerve causes increased firing as well as
impaired the efficiency of the inhibitory mechanisms that
control afferent activity in the trigeminal nucleus. The par-
oxysmal bursts of neuronal activity involve nociceptive
trigemino-thalamic relay neurons and excruciating pain is
experienced.
Another reason for the pain relief following botulinum
toxin treatment is conceivable: painful perception may be
secondary to the muscular spasm and caused by continu-
ous contraction of the muscle fibers [26]. The painful
muscle spasm is thought to be induced by regional muscle
ischemia due to compression of blood vessels. An altered
nociceptive processing is imaginable, leading to the per-
ception of pain in the affected overactive muscles. It is
assumed that continuous muscular contraction associated
with dystonic muscular disorders induces a severe chronic
pain syndrome [12]. Various disorders are often associ-
ated with painful sensations in the head and neck area
[3,6-12] such as cervical dystonia, spasticity, hemifacial
spasm, blepharospasm, temporomandibular joint syn-
drome or masseteric hypertrophy. The mechanisms of this
phenomenon are poorly understood. The positive phar-
macological effect could be thought to be achieved by var-
ious mechanisms: 1) blockage of cholinergic transmission
and interruption of muscle contractions [7], 2) decom-
pression of vascular nociceptive neurons, 3) normaliza-
tion of muscle spindle activity (inhibition of γ motor
endings [12]), or 4) modulation of central mechanisms
with regard to neuropeptides and neurogenic inflamma-
tion [15].
BTX-A injections lead to a direct attenuation of these mus-
cle contractions. An improvement in the aerobic muscular
metabolism with regard to oxygen supply has also been
postulated [6]. Cheshire [7] hypothesized that the benefi-
cial effect in myofascial pain occurs through the interrup-
tion of muscle contraction by cholinergic denervation.
According to Filippi [14], the most obvious mechanisms
by which pain relief may be mediated are through a reduc-
tion of muscle spasm by cholinergic chemodenervation at
motor end-plates and by inhibition of γ motor endings in
muscle spindles [14].
A further point of interest is the correlation between the
erythema in the affected area and the relief of this symp-
tom by treatment with BTX-A. Borodic et al. [1] made the
observation that the presence of erythematous patches or
facial edema associated with severe pain has often been
associated with the aggravation of pain. They discussed a
non-neuromuscular effect of BTX-A which blocks edema,
erythema, sensory discomfort and heat release and pro-
posed the possibility of anti-inflammatory properties of
botulinum toxin. Forty-four patients with chronic facial
pain (diagnoses: TMD, headache, post-surgical pain syn-
dromes, idiopathic trigeminal neuralgia) were treated
with botulinum toxin injections. In 72% of their patients,
they found erythematous discoloration or edema of the
painful areas of skin which improved following BTX-A
treatment. They noted that facial pains were frequently
associated with varying degrees and manifestations of
inflammatory responses and suggested this response to be
a mechanistic component of pain. The presence of edema
and erythema may be the outward physical signs of an
inflammatory process [1]. The presence of cutaneous ery-
thema suggests a pathogenesis involving inflammatory
phenomena that have been well known to occur in myo-
fascial pain syndrome, tension headache, temporoman-Publish with BioMed Central    and   every 
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dibular disease, migraine, trigeminal neuralgia and post-
surgical incisional pain syndromes.
Because the case described here showed a considerable
correlation between muscle hyperactivity and pain per-
ception, we hypothesize that facial pain may be induced
1) by mechanisms such as regional ischemia caused by
vascular compression through continuous muscle con-
traction, 2) altered processing of nociceptive stimuli or 3)
by irritation of trigeminal fibers following surgical trauma
and contraction of neighboring muscle fibers. There is no
clear explanation of why pressure applied to the retroau-
ricular and hand "alleviation points" is able to interrupt
the spasm and pain.
We conclude that injection of botulinum toxin type A is a
safe, effective and long-lasting method that can be effec-
tive in certain cases of facial pain syndromes associated
with muscular hyperactivity and inflammatory phenom-
ena. It is important to mention that neither reproducible
trials of the application of BTX-A for various forms of
headache have been conducted to date nor has the mech-
anism of action for pain application been conclusively
proven. For these reasons, the administration of BTX-A for
chronic facial pain (without dyskinesia) should be
reserved for those cases where conventional therapy
proves ineffective and symptoms are severe. In addition,
co-morbidity has to betaken into account. In such cases a
multidisciplinary approach is needed [27].
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
KJ performed clinical treatment, drafted the manuscript
and participated in the literature research and revision of
the manuscript. SR performed clinical treatment and par-
ticipated in the revision of manuscript. ME performed
clinical treatment and participated in the revision of the
manuscript. RL perormed clinical treatment, participated
in the literature research and revision of the manuscript
and supervised the clinical treatment and scientific
research. All authors read and approved the final manu-
script.
References
1. Borodic GE, Acquadro MA: The use of botulinum toxin for the
treatment of chronic facial pain.  J Pain 2002, 3:21-27.
2. Fromm GH, Terrence CF, Maroon JC: Trigeminal neuralgia. Cur-
rent concepts regarding etiology and pathogenesis.  Arch Neu-
rol 1984, 41:1204-1207.
3. Solomon S, Lipton RB: Facial pain.  Neurol Clin 1990, 8:913-928.
4. Remick RA, Blasberg B, Barton JS, Campos PE, Miles JE: Ineffective
dental and surgical treatment associated with atypical facial
pain.  Oral Surg Oral Med Oral Pathol 1983, 55:355-358.
5. Mock D, Frydman W, Gordon AS: Atypical facial pain: a retro-
spective study.  Oral Surg Oral Med Oral Pathol 1985, 59:472-474.
6. Künig G, Pogarell O, Oertel WH: Facial pain in a case of cranial
dystonia: a case report.  Cephalalgia 1998, 18:709-711.
7. Cheshire WP, Abashian SW, Mann JD: Botulinum toxin in the
treatment of myofascial pain syndrome.  Pain 1994, 59:65-69.
8. Girdler NM: Use of botulinum toxin to alleviate facial pain.  Br
J Hosp Med 1994, 52(7):363.
9. Von Lindern JJ, Niederhagen B, Bergé S, Appel T: Type Abotulinum
toxin in the treatment of chronic facial pain associated with
masticatory hyperactivity.  J Oral Maxillofac Surg 2003,
61:774-778.
10. Jankovic J, Schwartz K, Donovan DT: Botulinum toxin treatment
of cranial-cervical dystonia, spasmodic dysphonia, other
focal dystonias and hemifacial spasm.  J Neur Neurosurg Psychiatr
1990, 53(8):633-639.
11. Childers MK, Wilson DJ, Galate JF, Smith BK: Treatment of painful
muscle syndromes with botulinum toxin: a review.  J Back Mus-
culoskel Reh 1998, 10:89-96.
12. Guyer BM: Mechanism of botulinum toxin in the relief of
chronic pain.  Curr Rev Pain 1999, 3:427-431.
13. Jankovic J, Brin MF: Therapeutic uses of botulinum toxin.  N Engl
J Med 1991, 324(17):1186-1194.
14. Filippi GM, Errico P, Santarelli R, Bagolini B, Manni E: Botulinum A
toxin effects on rat jaws muscle spindles.  Acta Otolaryngol 1993,
113:400-404.
15. Göbel H, Jost WH: Botulinum toxin in specific pain therapy.
Schmerz 2003, 17:149-165.
16. Choi CH, Fisher WS III: Microvascular decompression as a ther-
apy for trigeminal neuralgia.  Microsurgery 1994, 15(8):527-533.
17. Laskawi R, Rohrbach S: Frey's syndrome. Treatment with bot-
ulinum toxin.  Curr Probl Dermatol 2002, 30:170-177.
18. Reichel G: Botulinum toxin A and the face.  Curr Probl Dermatol
2002, 30:236-245.
19. Lees AJ, Turjanski N, Rivest J, Whurr R, Lorch M, Brookes G: Treat-
ment of cervical dystonia, hand spasms and laryngeal dysto-
nia with botulinum toxin.  J Neurol 1992, 239:1-4.
20. Relja MA, Korsic M: Treatment of tension-type headache by
injections of botulinum toxin type A: double-blind placebo-
controlled study.  Neurology 1999, 52:A203.
21. Carruthers A, Langtry JAA, Carruthers J, Robinson G: Improve-
ment of tension-type headache when treating wrinkles with
botulinum toxin A injections.  Headache 1999, 39:662-665.
22. Relja M: Treatment of tension-type headache by local injec-
tion of botulinum toxin.  Eur J Neurol 1997, 4():S71-S73.
23. Schulte-Mattler WJ, Wieser T, Zierz S: Treatment of tension-
type headache with botulinum toxin: a pilot study.  Eur J Med
Res 1999, 4:183-186.
24. Tsui JKC, Eisen A, Stoessl AL, Calne S: Double-blind study of bot-
ulinum toxin in spasmodic torticollis.  Lancet 1986, 2:245-247.
25. Laskawi R: Spasmus facialis.  In Botulinumtoxin-Therapie im Kopf-
Hals-Bereich. 2. Aufl Edited by: Laskawi R, Roggenkämper P. München:
Urban und Vogel:90-101. 
26. Hallett M: Is dystonia a sensory disorder?  Ann Neurol 1995,
38:139-140.
27. Sipila K, Ylostalo PV, Joukamaa M, Knuuttila ML: Comorbidity
between facial pain, widespread pain, and depressive symp-
toms in young adults.  J Orofac Pain 2006, 20:24-30.